- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Pelthos Therapeutics ernennt John Gay zum neuen Finanzvorstand | 1 | Investing.com Deutsch | ||
| Fr | Pelthos Therapeutics names John Gay as chief financial officer | 1 | Investing.com | ||
| Fr | Pelthos Therapeutics names John M. Gay as CFO | 1 | Seeking Alpha | ||
| PELTHOS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces CFO Transition | 85 | GlobeNewswire (Europe) | DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet... ► Artikel lesen | |
| Fr | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Pelthos subsidiary doses first patient in eye pain trial | 2 | Investing.com | ||
| 31.03. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain | 220 | GlobeNewswire (Europe) | First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a... ► Artikel lesen | |
| 19.03. | Oppenheimer raises Pelthos Therapeutics price target to $62 on launch | 1 | Investing.com | ||
| 19.03. | Pelthos signals continued ZELSUVMI momentum and targets expanded product launches through 2027 | 1 | Seeking Alpha | ||
| 19.03. | Pelthos Therapeutics GAAP EPS of -$6.87 misses by $3.84, revenue of $9.39M beats by $0.3M | 1 | Seeking Alpha | ||
| 19.03. | Pelthos Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Pelthos Therapeutics Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 19.03. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results | 592 | GlobeNewswire (Europe) | ZELSUVMI net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December... ► Artikel lesen | |
| 09.03. | Pelthos Therapeutics, Inc.: Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 | 1 | GlobeNewswire (USA) | ||
| 27.02. | Piper Sandler initiates Pelthos stock with overweight rating | 1 | Investing.com | ||
| 27.02. | Piper Sandler startet Coverage für Pelthos mit "Overweight" und sieht deutliches Kurspotenzial | 2 | Investing.com Deutsch | ||
| 16.01. | Pelthos Therapeutics: Up To $50 Million Venture Loan Facility Secured From Horizon Technology Finance | 9 | pulse2.com | ||
| 15.01. | Horizon Technology Finance stellt Pelthos Therapeutics Darlehen über 50 Millionen US-Dollar bereit | 19 | Investing.com Deutsch | ||
| 15.01. | Horizon Technology Finance provides $50 million loan to Pelthos | 3 | Investing.com | ||
| 13.01. | Pelthos Therapeutics raises $50 mln senior secured loan facility | 1 | Seeking Alpha |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,530 | +0,09 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| MAINZ BIOMED | 0,443 | -6,24 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben |
Das Unternehmen PELTHOS THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 23,060 Euro und damit +1,81 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PELTHOS THERAPEUTICS INC finden Sie auf Wallstreet Online.